Bliss GVS Pharma Limited has announced a significant extension of its special window facility for shareholders seeking to re-lodge transfer requests for physical shares. The pharmaceutical company published this intimation in newspapers on April 04, 2026, in compliance with regulatory requirements.

Extension Details and Timeline

Following SEBI circular HO/38/13/11(2)2026-MIRSD-POD/3750/2026 dated January 30, 2026, the company has extended the special window facility that was previously available from July 07, 2025, to January 06, 2026. The new extended window provides shareholders with a fresh one-year period from February 05, 2026, to February 04, 2027.

Eligibility and Requirements

This facility is exclusively available for transfer deeds that were lodged before April 01, 2019, but were subsequently rejected, returned, or not attended to due to deficiencies in documents, processes, or other issues. Shareholders must ensure they have complete documentation when re-lodging their requests.

Important requirements include:

• Shares re-lodged during this period will be transferred only in demat mode
• Shareholders must have an active demat account
• Client Master List (CML) must be provided along with transfer documents

Contact Information and Process

Eligible shareholders can contact the company's Registrar and Share Transfer Agent (RTA), MUFG Intime India Private Limited (formerly Link Intime India Private Limited), at their office located at C-101, 247 Park, LBS Marg, Vikhroli West, Mumbai, Maharashtra-400083.

Regulatory Compliance

The newspaper publication was made in accordance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice was published in 'The Economic Times & The Free Press Journal' (English dailies) and 'Maharashtra Times & Navshakti' (regional dailies) on April 04, 2026.

The company has emphasized that eligible shareholders should submit their transfer requests duly completed in all respects on or before the SEBI deadline of February 04, 2027. This extension provides shareholders with additional time to complete the necessary documentation and processes for transferring their physical shares to demat mode.

Bliss GVS Pharma Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory obligations under SEBI depositories regulations for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The pharmaceutical company filed the mandatory certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, with both the National Stock Exchange of India Limited and BSE Limited on April 02, 2026.

Certificate Confirmation

MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, serving as the company's Registrar and Share Transfer Agent, issued the compliance certificate dated April 01, 2026. The certificate confirms that securities received from depository participants for dematerialisation during Q4FY26 were properly processed and confirmed to the depositories.

Key Compliance Confirmations

The registrar's certificate validates several critical compliance aspects:

• Securities received for dematerialisation were confirmed or rejected to depositories within prescribed timelines
• All securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialisation were properly mutilated and cancelled after due verification
• Depository names were substituted in the register of members as registered owners within regulatory timelines

Corporate Communication

Company Secretary Aditi Bhatt signed the filing letter, ensuring proper corporate governance protocols were followed. The submission was also copied to National Securities Depository Limited and Central Depository Services (India) Ltd, maintaining transparency with all relevant depositories.

This quarterly filing demonstrates Bliss GVS Pharma's commitment to maintaining regulatory compliance and ensuring transparent securities management processes for investor protection.